Clinical Trial Update: A Study of IMC-A12 in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of IMC-A12 in advanced solid tumors has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tumors

Drugs mentioned

• IMC-A12 (cixutumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Tumors | Phase 1 | Status: COMPLETED | Results posted: 2019-02-27